Harmony Biosciences LLC will expand narcolepsy community support efforts and reinforce its commitment to provide affordable access to treatment for people who have experienced a change in insurance or financial instability during the ongoing COVID-19 pandemic.
Its second annual “Patients at the Heart” grant program is being launched with increased funding to further support patient-centric organizations working to address the challenges of people living with narcolepsy during this time. The company’s patient support program will continue to provide medication free of charge for eligible patients who have lost health insurance or are underinsured, while providing contactless shipping for home delivery.
“At Harmony, patients are at the heart of everything we do, and we understand the financial and emotional difficulties faced by many people living with narcolepsy during this global pandemic,” says Cate McCanless, Harmony’s vice president, external affairs, in a release. “By moving up the launch of our second annual Patients at the Heart grant program we are offering additional funding to help improve the overall connectivity of people with narcolepsy and their support networks that are facing additional challenges in addressing the needs of the community during this unprecedented time.”
Harmony is accepting grant applications beginning Monday, April 27, 2020 with no deadline for submission. Grants will be awarded to applicants on a rolling basis. For more information, visit https://www.harmonybiosciences.com/about-us/grant-programs and submit grants to patientsattheheart[at]harmonybiosciences.com.
